Literature DB >> 21184858

Induction of immune memory by a multisubunit chlamydial vaccine.

F O Eko1, E Ekong, Q He, C M Black, J U Igietseme.   

Abstract

We tested the hypothesis that intramuscular immunization with a multisubunit chlamydial vaccine candidate will induce long lasting immune responses in mice. Accordingly, groups of female C57BL/6 mice were immunized intramuscularly with Vibrio cholerae ghosts (VCG) expressing the Poring B and polymorphic membrane protein-D proteins of Chlamydia trachomatis or a control antigen. Humoral and cell-mediated immune responses were evaluated following immunization and after live chlamydial infection. Immunization induced an anamnestic response characterized by chlamydial-specific IgG2a and IgA antibodies in sera and vaginal lavage as well as specific genital and splenic T cell responses. The results also revealed that the local mucosal and systemic cellular and humoral immune effectors induced in mice following immunization with the vaccine candidate are long lasting. Vaccinated mice cleared intravaginal challenge with 10(5) chlamydial inclusion forming units within 12 days compared to control mice, which shed up to 2 × 10(3) IFUs at this time point. Moreover, rechallenge of mice 98 days after resolution of the primary infection resulted in the recall and retention of a relatively high frequency of chlamydial-specific Th1 cells and IgG2a in the genital mucosa. These results provide the first evidence that a VCG-based multisubunit chlamydial vaccine is capable of effectively stimulating anamnestic systemic and mucosal immune responses in mice. The data support further vaccine evaluation and testing for induction of long-term protective immunity.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21184858      PMCID: PMC3032637          DOI: 10.1016/j.vaccine.2010.12.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  53 in total

Review 1.  Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens.

Authors:  Joseph U Igietseme; Francis O Eko; Qing He; Carolyn M Black
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

2.  A novel recombinant multisubunit vaccine against Chlamydia.

Authors:  Francis O Eko; Qing He; Teresa Brown; Lucinda McMillan; Godwin O Ifere; Godwin A Ananaba; Deborah Lyn; Werner Lubitz; Kathryn L Kellar; Carolyn M Black; Joseph U Igietseme
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

3.  Chlamydial serology in infertile women by immunofluorescence.

Authors:  R Punnonen; P Terho; V Nikkanen; O Meurman
Journal:  Fertil Steril       Date:  1979-06       Impact factor: 7.329

4.  An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response.

Authors:  Michael N Starnbach; Wendy P Loomis; Pam Ovendale; David Regan; Bruce Hess; Mark R Alderson; Steven P Fling
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

5.  Immune response to the Chlamydia trachomatis outer membrane protein PorB.

Authors:  Diane E Kawa; Julius Schachter; Richard S Stephens
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

6.  From the inside out--processing of the Chlamydial autotransporter PmpD and its role in bacterial adhesion and activation of human host cells.

Authors:  Wolfgang Wehrl; Volker Brinkmann; Peter R Jungblut; Thomas F Meyer; Agnes J Szczepek
Journal:  Mol Microbiol       Date:  2004-01       Impact factor: 3.501

7.  Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection.

Authors:  Linda J Berry; Danica K Hickey; Kathryn A Skelding; Shisan Bao; Amanda M Rendina; Philip M Hansbro; Christine M Gockel; Kenneth W Beagley
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

8.  Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway.

Authors:  Alexander Niessner; Christoph Kaun; Gerlinde Zorn; Walter Speidl; Zeynep Türel; Gunna Christiansen; Anna-Sofie Pedersen; Svend Birkelund; Susan Simon; Apostolos Georgopoulos; Wolfgang Graninger; Rainer de Martin; Joachim Lipp; Bernd R Binder; Gerald Maurer; Kurt Huber; Johann Wojta
Journal:  J Infect Dis       Date:  2003-06-12       Impact factor: 5.226

9.  Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.

Authors:  Francis O Eko; Werner Lubitz; Lucinda McMillan; Kiantra Ramey; Terri T Moore; Godwin A Ananaba; Deborah Lyn; Carolyn M Black; Joseph U Igietseme
Journal:  Vaccine       Date:  2003-04-02       Impact factor: 3.641

10.  A method for testing the specificity of influenza A virus-reactive memory cytotoxic T lymphocyte (CTL) clones in limiting dilution cultures.

Authors:  U Kees; G Kynast; E Weber; P H Krammer
Journal:  J Immunol Methods       Date:  1984-04-27       Impact factor: 2.303

View more
  13 in total

1.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

Review 2.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

3.  Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model.

Authors:  Qing Pan; Roshan Pais; Adaugo Ohandjo; Cheng He; Qing He; Yusuf Omosun; J U Igietseme; F O Eko
Journal:  Vaccine       Date:  2015-02-17       Impact factor: 3.641

Review 4.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

5.  Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection.

Authors:  Shanta Raj Bhattarai; So Young Yoo; Seung-Wuk Lee; Deborah Dean
Journal:  Biomaterials       Date:  2012-04-09       Impact factor: 12.479

6.  Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge.

Authors:  Zonghui Zuo; Yongjuan Zou; Qiang Li; Yongxia Guo; Tianyuan Zhang; Jie Wu; Cheng He; Francis O Eko
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

7.  Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity.

Authors:  Francis O Eko; Jayanti Mania-Pramanik; Roshan Pais; Qing Pan; Daniel M N Okenu; Arieian Johnson; Chris Ibegbu; Cheng He; Qing He; Raedeen Russell; Carolyn M Black; Joseph U Igietseme
Journal:  BMC Immunol       Date:  2014-12-31       Impact factor: 3.615

8.  Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge.

Authors:  Ulrike Beate Mayr; Pavol Kudela; Alena Atrasheuskaya; Eugenij Bukin; Georgy Ignatyev; Werner Lubitz
Journal:  Microb Biotechnol       Date:  2011-11-22       Impact factor: 5.813

9.  Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice.

Authors:  Wayne Paes; Naj Brown; Andrzej M Brzozowski; Rhea Coler; Steve Reed; Darrick Carter; Martin Bland; Paul M Kaye; Charles J N Lacey
Journal:  Vaccine       Date:  2016-07-04       Impact factor: 3.641

10.  Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine.

Authors:  Shakyra Richardson; Fnu Medhavi; Tayhlor Tanner; Stephanie Lundy; Yusuf Omosun; Joseph U Igietseme; Darin Carroll; Francis O Eko
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.